Anabolic agents: what is beyond osteoporosis?
Osteoporosis is a common skeletal disorder characterized by low bone mass, which leads to reduced bone strength and an increased risk of fractures. Anabolic agents have been shown to improve bone mass and decrease fracture risk in osteoporosis patients by directly stimulating osteoblasts to produce...
Gespeichert in:
| Veröffentlicht in: | Osteoporosis international 2018-05, Vol.29 (5), p.1009-1022 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1022 |
|---|---|
| container_issue | 5 |
| container_start_page | 1009 |
| container_title | Osteoporosis international |
| container_volume | 29 |
| creator | Liu, Y. Levack, A. E. Marty, E. Or, O. Samuels, B. P. Redko, M. Lane, J. M. |
| description | Osteoporosis is a common skeletal disorder characterized by low bone mass, which leads to reduced bone strength and an increased risk of fractures. Anabolic agents have been shown to improve bone mass and decrease fracture risk in osteoporosis patients by directly stimulating osteoblasts to produce new bone. Currently, two anabolic agents are available in the USA: recombinantly produced teriparatide (TPTD), which is the fully active (1–34) amino active sequence of human parathyroid hormone (PTH), and abaloparatide (APTD), a synthetic analog of parathyroid hormone-related peptide (PTHrP). At present, both agents are approved only for treatment of patients with osteoporosis at high risk of fracture. Nonetheless, their anabolic properties have led to off-label application in additional settings which include spine fusion, osteonecrosis of the jaw, arthroplasty, and fracture healing. In this article, we summarize available scientific literature regarding the efficacy, effectiveness, and safety of TPTD in these off-label settings. |
| doi_str_mv | 10.1007/s00198-018-4507-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5949085</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2023406980</sourcerecordid><originalsourceid>FETCH-LOGICAL-c536t-46118c0b0fbc3961c5cc5a11a58d007e9599eaab7cda7a25ff0804364f9cf6553</originalsourceid><addsrcrecordid>eNp1kUtPwzAQhC0EouXxA7igSFy4GNaJ7dgcQFXFS6rEBSRuluM6bao0LnEC6r_HUUp5SJx8mG_GuzsInRC4IADppQcgUmAgAlMGKRY7aEhokuBYcraLhiCTFEtKXgfowPsFBI-U6T4aBD1OhSRDhEeVzlxZmEjPbNX4q-hjrpuo8FFm166aRs431q1c7Xzhb47QXq5Lb4837yF6ubt9Hj_gydP943g0wYYlvMGUEyIMZJBnJpGcGGYM04RoJqZhBiuZlFbrLDVTneqY5TkIoAmnuTQ5Zyw5RNd97qrNlnZqwmS1LtWqLpa6XiunC_VbqYq5mrl3xSSVILqA801A7d5a6xu1LLyxZakr61qvYogTClwKCOjZH3Th2roK63VUnHIGkgaK9JQJl_C1zbfDEFBdGaovQ4UyVFeGEsFz-nOLrePr-gGIe8AHqZrZ-vvr_1M_AVgWlE0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2022765094</pqid></control><display><type>article</type><title>Anabolic agents: what is beyond osteoporosis?</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Liu, Y. ; Levack, A. E. ; Marty, E. ; Or, O. ; Samuels, B. P. ; Redko, M. ; Lane, J. M.</creator><creatorcontrib>Liu, Y. ; Levack, A. E. ; Marty, E. ; Or, O. ; Samuels, B. P. ; Redko, M. ; Lane, J. M.</creatorcontrib><description>Osteoporosis is a common skeletal disorder characterized by low bone mass, which leads to reduced bone strength and an increased risk of fractures. Anabolic agents have been shown to improve bone mass and decrease fracture risk in osteoporosis patients by directly stimulating osteoblasts to produce new bone. Currently, two anabolic agents are available in the USA: recombinantly produced teriparatide (TPTD), which is the fully active (1–34) amino active sequence of human parathyroid hormone (PTH), and abaloparatide (APTD), a synthetic analog of parathyroid hormone-related peptide (PTHrP). At present, both agents are approved only for treatment of patients with osteoporosis at high risk of fracture. Nonetheless, their anabolic properties have led to off-label application in additional settings which include spine fusion, osteonecrosis of the jaw, arthroplasty, and fracture healing. In this article, we summarize available scientific literature regarding the efficacy, effectiveness, and safety of TPTD in these off-label settings.</description><identifier>ISSN: 0937-941X</identifier><identifier>EISSN: 1433-2965</identifier><identifier>DOI: 10.1007/s00198-018-4507-8</identifier><identifier>PMID: 29627891</identifier><language>eng</language><publisher>London: Springer London</publisher><subject>Anabolic Agents - therapeutic use ; Arthroplasty - methods ; Bisphosphonate-Associated Osteonecrosis of the Jaw - drug therapy ; Bone Density Conservation Agents - therapeutic use ; Bone healing ; Bone mass ; Bone strength ; Endocrinology ; Fracture Healing - drug effects ; Fractures ; Humans ; Jaw ; Joint surgery ; Medicine ; Medicine & Public Health ; Off-Label Use ; Orthopedics ; Osteoblasts ; Osteonecrosis ; Osteoporosis ; Osteoporosis - drug therapy ; Parathyroid ; Parathyroid hormone ; Parathyroid hormone-related protein ; Patients ; Review ; Rheumatology ; Spinal Fusion - methods ; Spine ; Teriparatide - therapeutic use ; Vitamin D</subject><ispartof>Osteoporosis international, 2018-05, Vol.29 (5), p.1009-1022</ispartof><rights>International Osteoporosis Foundation and National Osteoporosis Foundation 2018</rights><rights>Osteoporosis International is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c536t-46118c0b0fbc3961c5cc5a11a58d007e9599eaab7cda7a25ff0804364f9cf6553</citedby><cites>FETCH-LOGICAL-c536t-46118c0b0fbc3961c5cc5a11a58d007e9599eaab7cda7a25ff0804364f9cf6553</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00198-018-4507-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00198-018-4507-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29627891$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Y.</creatorcontrib><creatorcontrib>Levack, A. E.</creatorcontrib><creatorcontrib>Marty, E.</creatorcontrib><creatorcontrib>Or, O.</creatorcontrib><creatorcontrib>Samuels, B. P.</creatorcontrib><creatorcontrib>Redko, M.</creatorcontrib><creatorcontrib>Lane, J. M.</creatorcontrib><title>Anabolic agents: what is beyond osteoporosis?</title><title>Osteoporosis international</title><addtitle>Osteoporos Int</addtitle><addtitle>Osteoporos Int</addtitle><description>Osteoporosis is a common skeletal disorder characterized by low bone mass, which leads to reduced bone strength and an increased risk of fractures. Anabolic agents have been shown to improve bone mass and decrease fracture risk in osteoporosis patients by directly stimulating osteoblasts to produce new bone. Currently, two anabolic agents are available in the USA: recombinantly produced teriparatide (TPTD), which is the fully active (1–34) amino active sequence of human parathyroid hormone (PTH), and abaloparatide (APTD), a synthetic analog of parathyroid hormone-related peptide (PTHrP). At present, both agents are approved only for treatment of patients with osteoporosis at high risk of fracture. Nonetheless, their anabolic properties have led to off-label application in additional settings which include spine fusion, osteonecrosis of the jaw, arthroplasty, and fracture healing. In this article, we summarize available scientific literature regarding the efficacy, effectiveness, and safety of TPTD in these off-label settings.</description><subject>Anabolic Agents - therapeutic use</subject><subject>Arthroplasty - methods</subject><subject>Bisphosphonate-Associated Osteonecrosis of the Jaw - drug therapy</subject><subject>Bone Density Conservation Agents - therapeutic use</subject><subject>Bone healing</subject><subject>Bone mass</subject><subject>Bone strength</subject><subject>Endocrinology</subject><subject>Fracture Healing - drug effects</subject><subject>Fractures</subject><subject>Humans</subject><subject>Jaw</subject><subject>Joint surgery</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Off-Label Use</subject><subject>Orthopedics</subject><subject>Osteoblasts</subject><subject>Osteonecrosis</subject><subject>Osteoporosis</subject><subject>Osteoporosis - drug therapy</subject><subject>Parathyroid</subject><subject>Parathyroid hormone</subject><subject>Parathyroid hormone-related protein</subject><subject>Patients</subject><subject>Review</subject><subject>Rheumatology</subject><subject>Spinal Fusion - methods</subject><subject>Spine</subject><subject>Teriparatide - therapeutic use</subject><subject>Vitamin D</subject><issn>0937-941X</issn><issn>1433-2965</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kUtPwzAQhC0EouXxA7igSFy4GNaJ7dgcQFXFS6rEBSRuluM6bao0LnEC6r_HUUp5SJx8mG_GuzsInRC4IADppQcgUmAgAlMGKRY7aEhokuBYcraLhiCTFEtKXgfowPsFBI-U6T4aBD1OhSRDhEeVzlxZmEjPbNX4q-hjrpuo8FFm166aRs431q1c7Xzhb47QXq5Lb4837yF6ubt9Hj_gydP943g0wYYlvMGUEyIMZJBnJpGcGGYM04RoJqZhBiuZlFbrLDVTneqY5TkIoAmnuTQ5Zyw5RNd97qrNlnZqwmS1LtWqLpa6XiunC_VbqYq5mrl3xSSVILqA801A7d5a6xu1LLyxZakr61qvYogTClwKCOjZH3Th2roK63VUnHIGkgaK9JQJl_C1zbfDEFBdGaovQ4UyVFeGEsFz-nOLrePr-gGIe8AHqZrZ-vvr_1M_AVgWlE0</recordid><startdate>20180501</startdate><enddate>20180501</enddate><creator>Liu, Y.</creator><creator>Levack, A. E.</creator><creator>Marty, E.</creator><creator>Or, O.</creator><creator>Samuels, B. P.</creator><creator>Redko, M.</creator><creator>Lane, J. M.</creator><general>Springer London</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180501</creationdate><title>Anabolic agents: what is beyond osteoporosis?</title><author>Liu, Y. ; Levack, A. E. ; Marty, E. ; Or, O. ; Samuels, B. P. ; Redko, M. ; Lane, J. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c536t-46118c0b0fbc3961c5cc5a11a58d007e9599eaab7cda7a25ff0804364f9cf6553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Anabolic Agents - therapeutic use</topic><topic>Arthroplasty - methods</topic><topic>Bisphosphonate-Associated Osteonecrosis of the Jaw - drug therapy</topic><topic>Bone Density Conservation Agents - therapeutic use</topic><topic>Bone healing</topic><topic>Bone mass</topic><topic>Bone strength</topic><topic>Endocrinology</topic><topic>Fracture Healing - drug effects</topic><topic>Fractures</topic><topic>Humans</topic><topic>Jaw</topic><topic>Joint surgery</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Off-Label Use</topic><topic>Orthopedics</topic><topic>Osteoblasts</topic><topic>Osteonecrosis</topic><topic>Osteoporosis</topic><topic>Osteoporosis - drug therapy</topic><topic>Parathyroid</topic><topic>Parathyroid hormone</topic><topic>Parathyroid hormone-related protein</topic><topic>Patients</topic><topic>Review</topic><topic>Rheumatology</topic><topic>Spinal Fusion - methods</topic><topic>Spine</topic><topic>Teriparatide - therapeutic use</topic><topic>Vitamin D</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Y.</creatorcontrib><creatorcontrib>Levack, A. E.</creatorcontrib><creatorcontrib>Marty, E.</creatorcontrib><creatorcontrib>Or, O.</creatorcontrib><creatorcontrib>Samuels, B. P.</creatorcontrib><creatorcontrib>Redko, M.</creatorcontrib><creatorcontrib>Lane, J. M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Osteoporosis international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Y.</au><au>Levack, A. E.</au><au>Marty, E.</au><au>Or, O.</au><au>Samuels, B. P.</au><au>Redko, M.</au><au>Lane, J. M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anabolic agents: what is beyond osteoporosis?</atitle><jtitle>Osteoporosis international</jtitle><stitle>Osteoporos Int</stitle><addtitle>Osteoporos Int</addtitle><date>2018-05-01</date><risdate>2018</risdate><volume>29</volume><issue>5</issue><spage>1009</spage><epage>1022</epage><pages>1009-1022</pages><issn>0937-941X</issn><eissn>1433-2965</eissn><abstract>Osteoporosis is a common skeletal disorder characterized by low bone mass, which leads to reduced bone strength and an increased risk of fractures. Anabolic agents have been shown to improve bone mass and decrease fracture risk in osteoporosis patients by directly stimulating osteoblasts to produce new bone. Currently, two anabolic agents are available in the USA: recombinantly produced teriparatide (TPTD), which is the fully active (1–34) amino active sequence of human parathyroid hormone (PTH), and abaloparatide (APTD), a synthetic analog of parathyroid hormone-related peptide (PTHrP). At present, both agents are approved only for treatment of patients with osteoporosis at high risk of fracture. Nonetheless, their anabolic properties have led to off-label application in additional settings which include spine fusion, osteonecrosis of the jaw, arthroplasty, and fracture healing. In this article, we summarize available scientific literature regarding the efficacy, effectiveness, and safety of TPTD in these off-label settings.</abstract><cop>London</cop><pub>Springer London</pub><pmid>29627891</pmid><doi>10.1007/s00198-018-4507-8</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0937-941X |
| ispartof | Osteoporosis international, 2018-05, Vol.29 (5), p.1009-1022 |
| issn | 0937-941X 1433-2965 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5949085 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Anabolic Agents - therapeutic use Arthroplasty - methods Bisphosphonate-Associated Osteonecrosis of the Jaw - drug therapy Bone Density Conservation Agents - therapeutic use Bone healing Bone mass Bone strength Endocrinology Fracture Healing - drug effects Fractures Humans Jaw Joint surgery Medicine Medicine & Public Health Off-Label Use Orthopedics Osteoblasts Osteonecrosis Osteoporosis Osteoporosis - drug therapy Parathyroid Parathyroid hormone Parathyroid hormone-related protein Patients Review Rheumatology Spinal Fusion - methods Spine Teriparatide - therapeutic use Vitamin D |
| title | Anabolic agents: what is beyond osteoporosis? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T18%3A26%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anabolic%20agents:%20what%20is%20beyond%20osteoporosis?&rft.jtitle=Osteoporosis%20international&rft.au=Liu,%20Y.&rft.date=2018-05-01&rft.volume=29&rft.issue=5&rft.spage=1009&rft.epage=1022&rft.pages=1009-1022&rft.issn=0937-941X&rft.eissn=1433-2965&rft_id=info:doi/10.1007/s00198-018-4507-8&rft_dat=%3Cproquest_pubme%3E2023406980%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2022765094&rft_id=info:pmid/29627891&rfr_iscdi=true |